Rimegepant 75 mg is Associated With Significant Reductions in Monthly Migraine Days: Post-Hoc Analyses of a Multicenter, Open Label Long-Term Safety Study of Rimegepant for the Acute Treatment of Migraine
HEADACHE（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要